Equities research analysts at Zacks Research dropped their FY2026 earnings estimates for Keysight Technologies in a research report issued on Tuesday, October 22nd. Zacks Research analyst R.

Boston Scientific (NYSE:BSX – Get Free Report) had its price target boosted by analysts at Morgan Stanley from $92.00 to $100 ...

Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), announces it will present its ADC candidates and ADC technology platforms at ...

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their ...